Former Medtronic CEO exits retirement early to helm Immucor

Brian Dunham | | Health Exec | Digital Transformation
William A. Hawkins, former chairman and CEO of Medtronic, will replace outgoing Immucor CEO Joshua Levine, after he steps down from the role Oct. 17, according to a statement from the company’s board of directors.

Hawkins’ career includes more than 30 years in medical technology companies, as well as roles in Washington, D.C., that helped shape healthcare policies and matters involving the FDA. Upon becoming CEO, Hawkins will also serve as senior advisor to TPG Capital, Immucor’s parent company.

Outgoing CEO Levine cited distance from his family as the reason for stepping down from the role.

The Norcross, Ga.-based company develops and sells reagents and systems used to detect and identify cell and serum components of human blood prior to blood transfusions.

Brian Dunham

Related Content

To tell or not to tell: Do patients really need to know who—or what—writes their doctor’s notes?
5 ways AI can help make healthcare more affordable for everyone
HIMSS survey report: Beware insider threats to cybersecurity involving AI
Primary care is primed for AI. But is AI aligned with primary care?
Machine learning vs. bodily pain: 5 points of promise and challenge
Generative AI isn’t changing everything for patients and providers—but it’s not leaving much unaffected, either

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.